Klk14 Antibody

What is KLK14 and why is it significant in cancer research?

KLK14 (Human Kallikrein 14) is a secreted serine protease belonging to the tissue kallikrein family. It has emerged as a significant biomarker in cancer research due to its differential expression patterns in various cancers. In breast cancer, KLK14 RNA expression has been found significantly more abundant in tumors compared to normal breast tissue . Similarly, in prostate cancer, KLK14 expression is elevated in advanced stages, particularly in metastasis . The significance of KLK14 lies in its potential as both a diagnostic and prognostic marker, as elevated expression has been associated with higher tumor grade and positive nodal status in breast cancer , and with aggressive features in prostate cancer progression .

How are anti-KLK14 antibodies typically generated for research purposes?

Anti-KLK14 antibodies for research applications are typically generated through immunization of animals with purified recombinant human KLK14. In one well-documented approach, New Zealand White female rabbits were immunized with 100 μg of purified recombinant human KLK14 produced in the Pichia pastoris expression system as the mature enzyme form . The immunization protocol involves:

• Initial injection of the protein diluted 1:1 in complete Freund's adjuvant

• Subsequent injections using incomplete Freund's adjuvant

• Repeating injections six times at 3-week intervals

• Blood collection and testing for antibody generation every 2 weeks

This approach generates polyclonal antibodies that can be used for various applications, including immunohistochemistry and western blotting. When developing KLK14 antibodies, special attention must be paid to potential cross-reactivity with other kallikrein family members, as these proteins share 30–50% sequence similarity .

What validation steps are essential when working with new KLK14 antibodies?

When working with newly developed KLK14 antibodies, thorough validation is crucial due to the high sequence similarity between kallikrein family members. Essential validation steps include:

• Cross-reactivity analysis: Testing against other KLK family proteins to ensure specificity

• Positive and negative controls: Using tissues or cell lines with known KLK14 expression patterns

• Multiple detection techniques: Confirming specificity across different applications (western blot, immunohistochemistry, ELISA)

• Antibody titration: Determining optimal concentration for specific applications

• Blocking experiments: Confirming specificity by pre-incubating with the recombinant KLK14 protein

The validation should include comparison of antibody performance on samples with different KLK14 expression levels, as demonstrated in studies examining KLK14 in normal breast tissue versus breast carcinomas or in different prostate cancer cell lines with varying metastatic potential .

What is the optimal protocol for KLK14 immunohistochemistry on formalin-fixed paraffin-embedded tissues?

For optimal KLK14 immunohistochemistry on formalin-fixed paraffin-embedded (FFPE) tissues, the following protocol has been successfully employed:

• Tissue preparation:

  • Cut fresh 4 μm sections from FFPE blocks

  • Mount on superfrost slides

  • Dewax with xylene and gradually hydrate

• Antigen retrieval:

  • Pressure cook in 0.01 M citrate buffer for 5 minutes

• Antibody application:

  • Dilute KLK14 antibody 1:1000 using a background reducing dilution buffer

  • Incubate at room temperature for 1 hour (no additional blocking agents required)

• Detection system:

  • Use conventional labeled-streptavidin-biotin method with alkaline phosphatase (ALP) as the reporting enzyme

  • Use Fast-Red as chromogen

  • Briefly counterstain with hematoxylin

This protocol has successfully demonstrated differential KLK14 expression between normal breast tissue (weak to intermediate expression in 91% of cases) and invasive breast carcinomas (stronger expression in 96% of cases) .

How can KLK14 activity be specifically detected in biological samples?

Detection of active KLK14 in biological samples can be achieved using activity-based probes and specialized blotting techniques. A recommended procedure includes:

• Sample preparation:

  • Collect conditioned media from cells expressing KLK14

  • Quantify total protein content and use a consistent amount (e.g., 10 μg)

• Activity-based labeling:

  • Treat samples with a biotinylated activity-based probe specific for KLK14 (e.g., compound X) for 2 hours

  • Add sample loading buffer and boil for 5 minutes

• Gel electrophoresis and transfer:

  • Run SDS-PAGE (10 min at 80 volts, 50 min at 180 volts)

  • Transfer to nitrocellulose membrane using wet transfer with Tris/glycine buffer containing 20% methanol

• Detection:

  • Wash membrane with TBS-T (1× TBS, 0.1% Tween-20)

  • Block with 3% BSA in TBS-T for 1 hour

  • Incubate with NeutrAvidin-HRP (1:1000 dilution in 0.3% BSA) for 1 hour

  • Wash with TBS-T (3 × 10 min)

  • Develop with Luminata Crescendo Western HRP substrate

This approach specifically detects the active form of KLK14, allowing differentiation between the inactive pro-enzyme and the proteolytically active form, which is crucial for functional studies.

What are the key considerations when designing proteolysis assays to identify KLK14 substrates?

When designing proteolysis assays to identify KLK14 substrates, several key considerations must be addressed:

• Enzyme activation:

  • Recombinant KLK14 often requires activation (e.g., using thermolysin as recommended by manufacturers)

  • Confirm activation status using activity-based probes or activity assays

• Experimental design options:

  • Dose-response assays: Incubate substrate proteins with increasing amounts of active KLK14 (molar ratios of enzyme:substrate from 1:100 to 1:5)

  • Kinetic assays: Incubate substrate proteins with active KLK14 (e.g., 1:50 ratio) for varying times (5, 15, 30, 60, and 120 min)

• Buffer conditions:

  • Use appropriate assay buffer (e.g., 50 mM Tris, 150 mM NaCl, 0.05% (w/v) Tween-20, pH 8.0)

• Controls:

  • Include substrate-only and enzyme-only controls

  • Consider including a catalytically inactive KLK14 mutant as negative control

• Analysis methods:

  • Stop reactions with Laemmli loading buffer containing β-mercaptoethanol

  • Analyze by SDS-PAGE followed by silver staining or western blotting

This approach has successfully identified several KLK14 substrates including agrin, desmoglein 2, vitronectin, and laminins .

How should KLK14 immunohistochemistry results be quantified and interpreted in cancer tissues?

Quantification and interpretation of KLK14 immunohistochemistry in cancer tissues should follow a systematic approach:

• Scoring system:

  • Evaluate staining intensity (negative, weak, moderate, strong)

  • Assess percentage of positive cells

  • Consider both cytoplasmic and potential nuclear localization separately

• Comparative analysis:

  • Compare expression between normal tissue, pre-malignant lesions, and invasive carcinoma within the same specimen when possible

  • In breast tissue studies, KLK14 expression was found to be significantly stronger in invasive carcinomas (96% positive) compared to normal breast tissues (91% positive but with weaker intensity)

• Correlation with clinicopathological parameters:

  • Analyze association with tumor grade, nodal status, hormone receptor status, and other relevant markers

  • KLK14 expression has been correlated with higher tumor grade (p=0.041) and positive nodal status (p value not fully provided in the source) in breast cancer

• Statistical analysis:

  • Use appropriate statistical tests (chi-square, Fisher's exact test) for categorical data

  • Apply survival analysis (Kaplan-Meier, log-rank test) to evaluate prognostic significance

• Validation:

  • Confirm protein expression findings with mRNA expression data when available

  • KLK14 RNA expression by real-time RT-PCR has been shown to be significantly more abundant in breast tumors compared to normal breast tissue (p=0.027)

What proteomics approaches are most effective for identifying and quantifying KLK14-regulated proteins?

The most effective proteomics approaches for identifying and quantifying KLK14-regulated proteins include:

• Terminal Amine Isobaric-Tag Labeling of Substrates (TAILS):

  • This technique enables enrichment of N-termini corresponding to natural protein N-termini or N-termini generated by proteolytic processing

  • Particularly useful for identifying protease substrates and cleavage sites

• Data acquisition and processing workflow:

  • Analyze raw files using proteome discoverer software against UniProtKB human protein database

  • Apply strict identification criteria: peptides identified in two PSM, in two biological replicates, quantified, not marked as contaminant, and with percolator q-value and FDR < 0.01

  • For quantification, use mean log2 ratio values and ANOVA analysis

• Statistical analysis and threshold determination:

  • Plot histogram of log2 ratios to check for normal distribution

  • Calculate standard deviation of log2 ratios

  • Use 2SD as cut-off to determine peptides with significant quantitative variations (p-value < 0.05)

Using this TAILS approach, a study identified and quantified 2067 peptides corresponding to 675 unique proteins, of which 23 proteins (3.4%) showed significant quantitative variations between active KLK14 and inactive mutant KLK14 conditions .

What is the significance of KLK14 substrate identification in understanding cancer progression?

The identification of KLK14 substrates provides critical insights into its role in cancer progression through several mechanisms:

• Extracellular Matrix Remodeling:

  • KLK14 has been shown to cleave key ECM components including vitronectin, agrin, laminins, and fibronectin

  • In prostate cancer studies, KLK14-modulated proteins revealed through proteomic analysis include:

• Cell Adhesion Modulation:

  • KLK14 affects membrane proteins involved in cellular adhesion such as:

    • Immunoglobulin superfamily member 8 (IGSF8, +2.2)

    • Spondin-2 (-1.5)

    • Cadherin-1 (-1.7)

• Pathway Activation:

  • Ingenuity Pathway Analysis of KLK14-modulated proteins indicated:

    • Activation of cellular functions related to cell motility and proliferation

    • Inhibition of functions related to cell death or infection

  • Involvement of mitogen-activated protein kinase 1 and interleukin 1 receptor pathways

• Biological Significance:

  • These findings explain the observed association between elevated KLK14 expression and:

    • Increased cancer cell migration

    • Development of aggressive prostate cancer

    • Potential role in metastasis formation

Understanding these substrate interactions provides molecular mechanisms for KLK14's role in cancer progression and may identify potential intervention targets.

How can KLK14 antibodies be combined with other techniques for multi-dimensional analysis of the tumor microenvironment?

KLK14 antibodies can be integrated into multi-dimensional analyses of the tumor microenvironment through several sophisticated approaches:

• Multiplex immunofluorescence staining:

  • Combine KLK14 antibodies with markers for:

    • Other proteases in the tumor microenvironment

    • Cell type-specific markers (epithelial, stromal, immune cells)

    • Signaling pathway components identified in KLK14 studies (e.g., MAPK1 pathway)

  • Protocol elements:

    • Sequential staining with appropriate fluorophore-conjugated secondary antibodies

    • Include DAPI for nuclear staining

    • Utilize phalloidin for actin cytoskeleton visualization

    • Use spinning disk confocal microscopy for high-resolution imaging

• Spatial transcriptomics integration:

  • Correlate KLK14 protein expression with spatial gene expression data

  • Map KLK14-regulated genes (e.g., Interleukin 32, midkine, SOX9) within the tumor architecture

• Single-cell analysis combined with KLK14 detection:

  • Identify which specific cell populations express KLK14

  • Correlate with cell states and phenotypic changes

  • Examine heterogeneity of KLK14 expression within tumors

• In situ proximity ligation assays (PLA):

  • Detect KLK14 interactions with identified substrates directly in tissue sections

  • Visualize KLK14-substrate complexes in their native microenvironment

These multi-dimensional approaches can provide insights into how KLK14 functions within the complex ecosystem of the tumor microenvironment, revealing spatial relationships and cellular interactions that may influence cancer progression.

What approaches are most effective for studying the regulation of KLK14 expression in response to hormonal changes?

For studying the regulation of KLK14 expression in response to hormonal changes, several effective approaches can be employed:

• Cell line models with controlled hormonal manipulation:

  • Use hormone-responsive cell lines (e.g., LNCaP prostate cancer cells)

  • Experimental conditions to compare:

    • Regular serum vs. charcoal-stripped serum (CSS, to remove endogenous hormones)

    • CSS + vehicle vs. CSS + hormone (e.g., 10 nM DHT for androgens)

    • Hormone vs. hormone + antagonist (e.g., enzalutamide for androgen receptor)

• Quantitative assessment methods:

  • mRNA expression: RTqPCR to measure KLK14 transcript levels

    • In LNCaP cells, KLK14 expression increased 4.0-fold after androgen deprivation

  • Protein expression: Western blot analysis of cellular and secreted KLK14

    • KLK14 was detected in secretome of LNCaP cells after androgen deprivation or anti-androgen treatment

• Hormone receptor binding studies:

  • Chromatin immunoprecipitation (ChIP) to identify hormone receptor binding sites in KLK14 regulatory regions

  • Reporter assays with KLK14 promoter constructs to assess transcriptional activation

• In vivo models:

  • Examine KLK14 expression in patient samples before and after hormonal therapy

  • KLK14 levels were found to be decreased in prostate cancer tissues from patients responsive to neoadjuvant therapy compared to untreated patients

  • KLK14 expression reoccurred in patients who developed castrate-resistant prostate cancer

These approaches provide complementary insights into the complex hormonal regulation of KLK14 expression, which is particularly relevant in hormone-dependent cancers like breast and prostate cancer.

What are the latest techniques for evaluating the therapeutic potential of targeting KLK14 in cancer?

Evaluating the therapeutic potential of targeting KLK14 in cancer involves several cutting-edge techniques:

• Genetic manipulation approaches:

  • Inducible expression systems:

    • Doxycycline-inducible promoters to control KLK14 expression

    • Compare wild-type KLK14 (iKLK14) with catalytic-mutant KLK14 (imKLK14)

  • CRISPR/Cas9 gene editing:

    • Generate KLK14 knockout cell lines

    • Create specific mutations in KLK14 catalytic domain

• Functional assays to assess phenotypic changes:

  • Migration assays: Evaluate effects on cell motility

  • Invasion assays: Determine impact on invasive capacity

  • 3D organoid cultures: Assess effects in more physiologically relevant models

• Protease inhibitor development and testing:

  • Activity-based probes (ABPs):

    • Use biotinylated KLK14-specific probes to confirm target engagement

    • Monitor inhibition efficiency in complex biological samples

  • High-throughput screening:

    • Identify small molecule inhibitors with specificity for KLK14

    • Evaluate selectivity against other kallikreins

• Combination therapy approaches:

  • Test KLK14 inhibition in combination with:

    • Hormone therapy (particularly relevant in prostate cancer where KLK14 expression is elevated in castrate-resistant disease)

    • Targeted therapies against pathways modulated by KLK14 (e.g., MAPK1 pathway)

    • Immunotherapies

• Translational biomarker development:

  • Develop assays to monitor KLK14 activity in patient samples

  • Correlate KLK14 expression/activity with treatment response

  • Identify patient subsets most likely to benefit from KLK14-targeted therapies

Research has shown that KLK14 expression is associated with aggressive prostate cancer development, suggesting that targeting this protease could offer a novel route to limit tumor progression . The development of specific KLK14 inhibitors, combined with appropriate patient selection based on KLK14 expression patterns, represents a promising therapeutic approach that warrants further investigation.